BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dewidar B, Kahl S, Pafili K, Roden M. Metabolic liver disease in diabetes - From mechanisms to clinical trials. Metabolism 2020;111S:154299. [PMID: 32569680 DOI: 10.1016/j.metabol.2020.154299] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 8.5] [Reference Citation Analysis]
Number Citing Articles
1 Shi GY, Sun Y, Liang XC, Xie JD. Clinical significance of expression of serum insulin-like growth factor-1 in patients with primary liver cancer and diabetes mellitus. Shijie Huaren Xiaohua Zazhi 2021; 29(5): 236-241 [DOI: 10.11569/wcjd.v29.i5.236] [Reference Citation Analysis]
2 Mantovani A, Dalbeni A. Treatments for NAFLD: State of Art. Int J Mol Sci 2021;22:2350. [PMID: 33652942 DOI: 10.3390/ijms22052350] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
3 Yang L, Liu D, Yan H, Chen K. Dapagliflozin attenuates cholesterol overloading-induced injury in mice hepatocytes with type 2 diabetes mellitus (T2DM) via eliminating oxidative damages. Cell Cycle 2022;:1-14. [PMID: 35100086 DOI: 10.1080/15384101.2022.2031429] [Reference Citation Analysis]
4 Sun YL, Shang LR, Liu RH, Li XY, Zhang SH, Ren YK, Fu K, Cheng HB, Yahaya BH, Liu YL, Lin JT. Therapeutic effects of menstrual blood-derived endometrial stem cells on mouse models of streptozotocin-induced type 1 diabetes. World J Stem Cells 2022; 14(1): 104-116 [DOI: 10.4252/wjsc.v14.i1.104] [Reference Citation Analysis]
5 Kahl S, Pützer J, Roden M. Novel Antidiabetic Strategies and Diabetologists' Views in Nonalcoholic Steatohepatitis. Semin Liver Dis 2021. [PMID: 34289506 DOI: 10.1055/s-0041-1732354] [Reference Citation Analysis]
6 Polyzos SA, Mantzoros CS. Making progress in nonalcoholic fatty liver disease (NAFLD) as we are transitioning from the era of NAFLD to dys-metabolism associated fatty liver disease (DAFLD). Metabolism 2020;111S:154318. [PMID: 32707055 DOI: 10.1016/j.metabol.2020.154318] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
7 Sphabmixay P, Raredon MSB, Wang AJ, Lee H, Hammond PT, Fang NX, Griffith LG. High resolution stereolithography fabrication of perfusable scaffolds to enable long-term meso-scale hepatic culture for disease modeling. Biofabrication 2021;13. [PMID: 34479229 DOI: 10.1088/1758-5090/ac23aa] [Reference Citation Analysis]
8 Qu W, Ma T, Cai J, Zhang X, Zhang P, She Z, Wan F, Li H. Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies. Front Med (Lausanne) 2021;8:761538. [PMID: 34746195 DOI: 10.3389/fmed.2021.761538] [Reference Citation Analysis]
9 Chen C, Kang M, Wang Q, Liu W, Yang M, Liang S, Xiang Q, Han X, Tao J. Combination of Anoectochilus roxburghii Polysaccharide and Exercise Ameliorates Diet-Induced Metabolic Disorders in Obese Mice. Front Nutr 2021;8:735501. [PMID: 34692748 DOI: 10.3389/fnut.2021.735501] [Reference Citation Analysis]
10 Chen J, Ding X, Wu R, Tong B, Zhao L, Lv H, Meng X, Liu Y, Ren B, Li J, Jian T, Li W. Novel Sesquiterpene Glycoside from Loquat Leaf Alleviates Type 2 Diabetes Mellitus Combined with Nonalcoholic Fatty Liver Disease by Improving Insulin Resistance, Oxidative Stress, Inflammation, and Gut Microbiota Composition. J Agric Food Chem 2021;69:14176-91. [PMID: 34783554 DOI: 10.1021/acs.jafc.1c05596] [Reference Citation Analysis]
11 Kim K, Oh TJ, Cho HC, Lee YK, Ahn CH, Koo BK, Moon JH, Choi SH, Jang HC. Liver fibrosis indices are related to diabetic peripheral neuropathy in individuals with type 2 diabetes. Sci Rep 2021;11:24372. [PMID: 34934162 DOI: 10.1038/s41598-021-03870-z] [Reference Citation Analysis]
12 Pafili K, Paschou SA, Armeni E, Polyzos SA, Goulis DG, Lambrinoudaki I. Non-alcoholic fatty liver disease through the female lifespan: the role of sex hormones. J Endocrinol Invest 2022. [PMID: 35303270 DOI: 10.1007/s40618-022-01766-x] [Reference Citation Analysis]
13 Pivovarova-Ramich O, Loske J, Hornemann S, Markova M, Seebeck N, Rosenthal A, Klauschen F, Castro JP, Buschow R, Grune T, Lange V, Rudovich N, Ouwens DM. Hepatic Wnt1 Inducible Signaling Pathway Protein 1 (WISP-1/CCN4) Associates with Markers of Liver Fibrosis in Severe Obesity. Cells 2021;10:1048. [PMID: 33946738 DOI: 10.3390/cells10051048] [Reference Citation Analysis]
14 Harreiter J, Just I, Leutner M, Bastian M, Brath H, Schelkshorn C, Klepochova R, Krššák M, Kautzky-Willer A. Combined exenatide and dapagliflozin has no additive effects on reduction of hepatocellular lipids despite better glycaemic control in patients with type 2 diabetes mellitus treated with metformin: EXENDA, a 24-week, prospective, randomized, placebo-controlled pilot trial. Diabetes Obes Metab 2021;23:1129-39. [PMID: 33464703 DOI: 10.1111/dom.14319] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
15 Mastrototaro L, Roden M. Insulin resistance and insulin sensitizing agents. Metabolism 2021;125:154892. [PMID: 34563556 DOI: 10.1016/j.metabol.2021.154892] [Reference Citation Analysis]
16 Ding W, Liu H, Qin Z, Liu M, Zheng M, Cai D, Liu J. Dietary Antioxidant Anthocyanins Mitigate Type II Diabetes through Improving the Disorder of Glycometabolism and Insulin Resistance. J Agric Food Chem 2021;69:13350-63. [PMID: 34730960 DOI: 10.1021/acs.jafc.1c05630] [Reference Citation Analysis]
17 Schröder B, Kahl S, Roden M. Non-alcoholic fatty liver disease in type 2 diabetes - A specific entity? Liver Int 2021;41 Suppl 1:105-11. [PMID: 34155798 DOI: 10.1111/liv.14846] [Reference Citation Analysis]
18 Scalcon V, Folda A, Lupo MG, Tonolo F, Pei N, Battisti I, Ferri N, Arrigoni G, Bindoli A, Holmgren A, Coppo L, Rigobello MP. Mitochondrial depletion of glutaredoxin 2 induces metabolic dysfunction-associated fatty liver disease in mice. Redox Biology 2022. [DOI: 10.1016/j.redox.2022.102277] [Reference Citation Analysis]
19 Prokopidis K, Witard OC. Understanding the role of smoking and chronic excess alcohol consumption on reduced caloric intake and the development of sarcopenia. Nutr Res Rev 2021;:1-10. [PMID: 34027849 DOI: 10.1017/S0954422421000135] [Reference Citation Analysis]
20 Ayaz T, Polat HB, Kilictas B. Evaluation of the reciprocal interaction between hepatic steatosis and type 2 diabetes: a comparative analysis with respect to anti-diabetic treatment, glycemic control, renal and hepatic function. Int J Diabetes Dev Ctries. [DOI: 10.1007/s13410-021-01009-4] [Reference Citation Analysis]
21 Xue C, Li Y, Lv H, Zhang L, Bi C, Dong N, Shan A, Wang J. Oleanolic Acid Targets the Gut-Liver Axis to Alleviate Metabolic Disorders and Hepatic Steatosis. J Agric Food Chem 2021;69:7884-97. [PMID: 34251802 DOI: 10.1021/acs.jafc.1c02257] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
22 Li H, Xu Q, Xu C, Hu Y, Yu X, Zhao K, Li M, Li M, Xu J, Kuang H. Bicyclol Regulates Hepatic Gluconeogenesis in Rats with Type 2 Diabetes and Non-alcoholic Fatty Liver Disease by Inhibiting Inflammation. Front Pharmacol 2021;12:644129. [PMID: 34093184 DOI: 10.3389/fphar.2021.644129] [Reference Citation Analysis]
23 Lee H, Cho S, Kang A, Shin DH, Park HY, Jeong TS. Combination Treatment of Arazyme and Soy Leaf Extract Attenuates Hyperglycemia and Hepatic Steatosis in High-Fat Diet-Fed C57BL/6J Mice. Life (Basel) 2021;11:645. [PMID: 34357017 DOI: 10.3390/life11070645] [Reference Citation Analysis]
24 Rajewski P, Zarębska-Michaluk D, Janczewska E, Gietka A, Mazur W, Tudrujek-Zdunek M, Tomasiewicz K, Belica-Wdowik T, Baka-Ćwierz B, Dybowska D, Halota W, Lorenc B, Sitko M, Garlicki A, Berak H, Horban A, Orłowska I, Simon K, Socha Ł, Wawrzynowicz-Syczewska M, Jaroszewicz J, Deroń Z, Czauż-Andrzejuk A, Citko J, Krygier R, Piekarska A, Laurans Ł, Dobracki W, Białkowska J, Tronina O, Wietlicka-Piszcz M, Pawłowska M, Flisiak R. HCV Genotype Has No Influence on the Incidence of Diabetes-EpiTer Multicentre Study. J Clin Med 2022;11:379. [PMID: 35054072 DOI: 10.3390/jcm11020379] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Ishizu Y, Ishigami M, Honda T, Imai N, Ito T, Yamamoto K, Fujishiro M. Impact of visceral fat accumulation on the prognosis of patients with cirrhosis. Clin Nutr ESPEN 2021;42:354-60. [PMID: 33745605 DOI: 10.1016/j.clnesp.2021.01.008] [Reference Citation Analysis]
26 Thomas DT, Delcimmuto NR, Flack KD, Stec DE, Hinds TD. Reactive Oxygen Species (ROS) and Antioxidants as Immunomodulators in Exercise: Implications for Heme Oxygenase and Bilirubin. Antioxidants 2022;11:179. [DOI: 10.3390/antiox11020179] [Reference Citation Analysis]
27 Guan H, Zhang J, Luan J, Xu H, Huang Z, Yu Q, Gou X, Xu L. Secreted Frizzled Related Proteins in Cardiovascular and Metabolic Diseases. Front Endocrinol (Lausanne) 2021;12:712217. [PMID: 34489867 DOI: 10.3389/fendo.2021.712217] [Reference Citation Analysis]
28 Makri ES, Goulas A, Polyzos SA. Sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease. Eur J Pharmacol 2021;907:174272. [PMID: 34147478 DOI: 10.1016/j.ejphar.2021.174272] [Reference Citation Analysis]
29 Ziolkowska S, Binienda A, Jabłkowski M, Szemraj J, Czarny P. The Interplay between Insulin Resistance, Inflammation, Oxidative Stress, Base Excision Repair and Metabolic Syndrome in Nonalcoholic Fatty Liver Disease. Int J Mol Sci 2021;22:11128. [PMID: 34681787 DOI: 10.3390/ijms222011128] [Reference Citation Analysis]
30 Pafili K, Roden M. Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans. Mol Metab 2021;50:101122. [PMID: 33220492 DOI: 10.1016/j.molmet.2020.101122] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
31 Kozawa J, Shimomura I. Ectopic Fat Accumulation in Pancreas and Heart. J Clin Med 2021;10:1326. [PMID: 33806978 DOI: 10.3390/jcm10061326] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
32 Nickel NP, Galura GM, Zuckerman MJ, Hakim MN, Alkhateeb H, Mukherjee D, Austin ED, Heresi GD. Liver abnormalities in pulmonary arterial hypertension. Pulm Circ 2021;11:20458940211054304. [PMID: 34707859 DOI: 10.1177/20458940211054304] [Reference Citation Analysis]
33 Alghamdi F, Alshuweishi Y, Salt IP. Regulation of nutrient uptake by AMP-activated protein kinase. Cellular Signalling 2020;76:109807. [DOI: 10.1016/j.cellsig.2020.109807] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
34 Nasiri-Ansari N, Nikolopoulou C, Papoutsi K, Kyrou I, Mantzoros CS, Kyriakopoulos G, Chatzigeorgiou A, Kalotychou V, Randeva MS, Chatha K, Kontzoglou K, Kaltsas G, Papavassiliou AG, Randeva HS, Kassi E. Empagliflozin Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) in High Fat Diet Fed ApoE(-/-) Mice by Activating Autophagy and Reducing ER Stress and Apoptosis. Int J Mol Sci 2021;22:E818. [PMID: 33467546 DOI: 10.3390/ijms22020818] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]